US 12,257,262 B2
Method of reconstituting liposomal annamycin
Donald Picker, Albany, NY (US); and Waldemar Priebe, Houston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US); and Moleculin Biotech, Inc., Houston, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US); and Moleculin Biotech, Inc., Houston, TX (US)
Filed on Dec. 17, 2021, as Appl. No. 17/554,553.
Application 17/554,553 is a continuation of application No. PCT/US2020/039621, filed on Jun. 25, 2020.
Claims priority of provisional application 62/868,190, filed on Jun. 28, 2019.
Prior Publication US 2022/0105116 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/704 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01)
CPC A61K 31/704 (2013.01) [A61K 9/0019 (2013.01); A61K 9/127 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of reconstituting Annamycin, such method comprising:
adding saline at 37° C. ±4° C. to one or more containers of preliposomal Annamycin lyophilizate, to form suspended liposomal Annamycin with a concentration of 0.5-1.5 mg/mL;
maintaining said one or more containers at 37° C. ±4° C.;
diluting said suspended liposomal Annamycin, with saline at 37° C. ±4° C. to provide diluted liposomal Annamycin at a concentration in saline of 0.3-0.7 mg/mL; and
maintaining said one or more containers of suspended liposomal Annamycin and said diluted liposomal Annamycin at 37° C. ±4° C. during and after the dilution.